Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00977665 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
A Phase 2 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 174
- Enrollment target
NCT00977665 is a Phase 2 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 174 participants.
The verdict
NCT00977665, a Phase 2 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 174 participants
- Enrollment target
Study Summary
To test the clinical effect of rasagiline on subjects with MSA of the parkinsonian subtype.
Interventions
- DRUG placebo
- DRUG rasagiline mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00977665
The ClinicalTrials.gov registry entry for NCT00977665 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00977665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00977665 about?
NCT00977665 is a clinical study titled "Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)". To test the clinical effect of rasagiline on subjects with MSA of the parkinsonian subtype.
What is the current status of trial NCT00977665?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2009-12. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00977665?
The interventions under investigation include: placebo (DRUG), rasagiline mesylate (DRUG).
Who is sponsoring clinical trial NCT00977665?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.